Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss ongoing research and areas of potential investigation in ovarian cancer.
Tiffany Redfern, MD, FACOG
Advertisement
Tiffany Redfern, MD, FACOG, is a gynecologic oncologist at Texas Oncology in Austin.
Articles by Tiffany Redfern, MD, FACOG
Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss updates in ovarian cancer from the 2025 SGO Annual Meeting.
Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss other potential roles for mirvetuximab soravtansine in ovarian cancer.
Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, on patient-reported outcome data for mirvetuximab soravtansine in platinum-resistant ovarian cancer.
MIRASOL Trial: Final OS Data for Mirvetuximab Soravtansine in FRa+ Platinum-Resistant Ovarian Cancer
Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, on final overall survival data for mirvetuximab soravtansine in platinum-resistant ovarian cancer.
Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss current treatment approached in platinum-resistant ovarian cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL
5